Medical/Pharmaceuticals

Samsung Biologics Reports First Quarter 2021 Financial Results

* Q1'21 revenue of KRW 260.8 billion increased 26% compared to Q1'20. * Q1'21 operating profit of KRW 74.3 billion increased 19% compared to Q1'20. * Q1'21 operating margin held steady at 28%. * All manufacturing facilities remain fully operational, without any disruptions caused by the COV...

2021-04-28 16:37 4354

New Distribution Facility Expands Bushu Pharma's Gateway to Asia (GTA) Services

KAWAGOE, Japan, April 28, 2021 /PRNewswire/ -- Bushu Pharmaceuticals Ltd. (hereinafter "Bushu Pharma") has established the Bushu Pharma Kazo Packaging Center located within the Kazo Pharmaceuticals Joint Distribution Center of Chuo Unyu Company ("Chuo Unyu") to carry out inspection, labeling, pac...

2021-04-28 14:00 1032

Bushu Pharma's Collaboration with Suzuken Group Expands Services for Specialty Pharmaceuticals

KAWAGOE, Japan, April 27, 2021 /PRNewswire/ -- -Establishment of New Business Alliance and Facility to Provide Comprehensive Support for New Product Launches for Manufacturers Aiming to Enter Japan Market- Bushu Pharmaceuticals Ltd. (hereinafter "Bushu Pharma") has entered into a business allian...

2021-04-27 14:00 1672

PharmAbcine to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

DAEJEON, South Korea, April 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will present an e-poster featuring non-clinical data of PMC-403 at the Association for ...

2021-04-26 20:00 1481

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center...

2021-04-26 19:00 1678

Peijia Medical's TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization

SUZHOU, China, April 24, 2021 /PRNewswire/ -- A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne® Transcatheter Aortic Valve Replacement System (hereinafter referred to as "TaurusOne®") developed by Peijia Medical (Suz...

2021-04-25 08:53 2586

Ronovo Surgical Completes Series A Financing, Aims to Transform Surgery with Innovations Focused on Simplicity, Precision and Intelligence.

SHANGHAI, April 23, 2021 /PRNewswire/ -- Ronovo Surgical, an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery to address the tremendous needs of the Chinese surgical market, recently announced successful closing of Series A financing. Developed by renow...

2021-04-23 22:00 3090

Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression

TOKYO, April 23, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good") and Teijin Pharma Ltd. ("Teijin Pharma") have signed a business partnership agreement to develop VR digital therapeutics ("VR DTx") for Major Depressive Disorder (MDD). Together, they will promote the development of VR DTx for d...

2021-04-23 21:00 2620

Wuxi Strives to Build a World-class Biomedical Industry Chain

WUXI, China, April 22, 2021 /PRNewswire/ -- From April 21 to 23, the 2021 Taihu Bay Future Healthcare Conference was held in Wuxi,China. More than 160 experts including Hejie, Fan Chunhai and many other academicians carried out forward-looking, authoritative, and predictive exchanges and dialogue...

2021-04-22 19:06 976

111 to Announce First Quarter 2021 Unaudited Financial Results on May 19, 2021 - Conference Call to Follow

SHANGHAI, April 21, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...

2021-04-21 20:00 2103

Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research

LOS ANGELES, April 21, 2021 /PRNewswire/ -- Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40 million Series A financing led by impact investor,The Craftory, alongside TechBio investor ARTIS Ven...

2021-04-21 20:00 2739

Samsung Biologics Celebrates Its 10th Anniversary with Its Mission, "Driven. For Life."

INCHEON, South Korea, April 21, 2021 /PRNewswire/ -- Samsung Biologics, the world's leading contract development and manufacturing organization, celebrated the 10th anniversary of its founding today at its global headquarters in Songdo, Incheon via a virtual ceremony.

2021-04-21 19:00 1358

China Biologic Announces Completion of Going Private Transaction

BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger...

2021-04-21 04:30 4561

Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005

SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of i...

2021-04-20 20:54 1024

AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration

SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolyti...

2021-04-20 08:30 1496

Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform

LAKEWOOD, Colo. and BOCA RATON, Fla., April 19, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device ...

2021-04-20 05:00 2142

China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Rel...

2021-04-19 20:30 2885

CNPharm has succeeded in maintaining IC100 for 24 hours with one injection

- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...

2021-04-19 20:15 1422

Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy

SUZHOU, China, April 19, 2021 /PRNewswire/ -- On April 16, 2021, Suzhou Porton BiologicsLtd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO se...

2021-04-19 20:00 4309

PharmAbcine announces Clinical Trial Collaboration with MSD for the Phase II study in mTNBC

DAEJEON, South Korea, April 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has entered into an agreement with MSD to initiate a Phase II combination trial of olin...

2021-04-19 20:00 1349
1 ... 151152153154155156157 ... 199